A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells

Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, Masayuki Yamato

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from the processing of human embryonic stem cells (hESCs), taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-6, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from hESCs, in addition to similar points to consider that are described previously for allogeneic human stem cell-based products. Major additional points include 1) establishment of hESCs; 2) establishment of stable and well-characterized cell banks of hESCs and relevant intermediate cell products; 3) concerns about the presence of undifferentiated cells in final products, which may result in ectopic tissue formation and/or tumorigenesis; and 4) concerns about undesirable immunological reactions caused by the final products. The ultimate goal of this series of guidelines on regenerative medicine is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities. If these guidelines are interpreted and employed in a flexible and meaningful way in this context, they should serve as a useful means to achieve their goals.

Original languageEnglish
Pages (from-to)109-122
Number of pages14
JournalRegenerative Therapy
Volume2
DOIs
Publication statusPublished - 01-12-2015

Fingerprint

Equipment Safety
Stem cells
Drug products
Processing
Regenerative Medicine
Pharmaceutical Preparations
Stem Cells
Guidelines
Choristoma
Food Safety
Ethics
Japan
Carcinogenesis
Food safety
Human Embryonic Stem Cells
Safety
Health
Acoustic waves
Personnel
Tissue

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering
  • Developmental Biology

Cite this

Hayakawa, Takao ; Aoi, Takashi ; Umezawa, Akihiro ; Ozawa, Keiya ; Sato, Yoji ; Sawa, Yoshiki ; Matsuyama, Akifumi ; Yamanaka, Shinya ; Yamato, Masayuki. / A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells. In: Regenerative Therapy. 2015 ; Vol. 2. pp. 109-122.
@article{2bce48c764274dc481c67a800fea3d75,
title = "A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells",
abstract = "As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from the processing of human embryonic stem cells (hESCs), taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-6, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from hESCs, in addition to similar points to consider that are described previously for allogeneic human stem cell-based products. Major additional points include 1) establishment of hESCs; 2) establishment of stable and well-characterized cell banks of hESCs and relevant intermediate cell products; 3) concerns about the presence of undifferentiated cells in final products, which may result in ectopic tissue formation and/or tumorigenesis; and 4) concerns about undesirable immunological reactions caused by the final products. The ultimate goal of this series of guidelines on regenerative medicine is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities. If these guidelines are interpreted and employed in a flexible and meaningful way in this context, they should serve as a useful means to achieve their goals.",
author = "Takao Hayakawa and Takashi Aoi and Akihiro Umezawa and Keiya Ozawa and Yoji Sato and Yoshiki Sawa and Akifumi Matsuyama and Shinya Yamanaka and Masayuki Yamato",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.reth.2015.06.001",
language = "English",
volume = "2",
pages = "109--122",
journal = "Regenerative Therapy",
issn = "2352-3204",
publisher = "Japanese Society of Regenerative Medicine",

}

A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells. / Hayakawa, Takao; Aoi, Takashi; Umezawa, Akihiro; Ozawa, Keiya; Sato, Yoji; Sawa, Yoshiki; Matsuyama, Akifumi; Yamanaka, Shinya; Yamato, Masayuki.

In: Regenerative Therapy, Vol. 2, 01.12.2015, p. 109-122.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells

AU - Hayakawa, Takao

AU - Aoi, Takashi

AU - Umezawa, Akihiro

AU - Ozawa, Keiya

AU - Sato, Yoji

AU - Sawa, Yoshiki

AU - Matsuyama, Akifumi

AU - Yamanaka, Shinya

AU - Yamato, Masayuki

PY - 2015/12/1

Y1 - 2015/12/1

N2 - As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from the processing of human embryonic stem cells (hESCs), taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-6, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from hESCs, in addition to similar points to consider that are described previously for allogeneic human stem cell-based products. Major additional points include 1) establishment of hESCs; 2) establishment of stable and well-characterized cell banks of hESCs and relevant intermediate cell products; 3) concerns about the presence of undifferentiated cells in final products, which may result in ectopic tissue formation and/or tumorigenesis; and 4) concerns about undesirable immunological reactions caused by the final products. The ultimate goal of this series of guidelines on regenerative medicine is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities. If these guidelines are interpreted and employed in a flexible and meaningful way in this context, they should serve as a useful means to achieve their goals.

AB - As a series of endeavors to establish suitable measures for the sound development of regenerative medicine using human stem cell-based products, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from the processing of human embryonic stem cells (hESCs), taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-6, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on September 7, 2012. The present paper addresses various aspects of products derived from hESCs, in addition to similar points to consider that are described previously for allogeneic human stem cell-based products. Major additional points include 1) establishment of hESCs; 2) establishment of stable and well-characterized cell banks of hESCs and relevant intermediate cell products; 3) concerns about the presence of undifferentiated cells in final products, which may result in ectopic tissue formation and/or tumorigenesis; and 4) concerns about undesirable immunological reactions caused by the final products. The ultimate goal of this series of guidelines on regenerative medicine is to provide suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to treat with conventional modalities. If these guidelines are interpreted and employed in a flexible and meaningful way in this context, they should serve as a useful means to achieve their goals.

UR - http://www.scopus.com/inward/record.url?scp=84995722046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995722046&partnerID=8YFLogxK

U2 - 10.1016/j.reth.2015.06.001

DO - 10.1016/j.reth.2015.06.001

M3 - Article

AN - SCOPUS:84995722046

VL - 2

SP - 109

EP - 122

JO - Regenerative Therapy

JF - Regenerative Therapy

SN - 2352-3204

ER -